Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2006 2
2007 2
2008 2
2009 6
2010 5
2011 4
2012 5
2013 8
2014 2
2015 14
2016 17
2017 5
2018 9
2019 5
2020 1
2021 2
2022 4
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 30046049

91 results

Results by year

Filters applied: . Clear all
Page 1
Maintenance treatment in metastatic colorectal cancer.
Chibaudel B, Bonnetain F, Tournigand C, de Gramont A. Chibaudel B, et al. Lancet Oncol. 2015 Dec;16(16):e583-4. doi: 10.1016/S1470-2045(15)00448-9. Lancet Oncol. 2015. PMID: 26678202 No abstract available.
Maintenance treatment in metastatic colorectal cancer.
Simkens LH, van Tinteren H, Punt CJ, Koopman M. Simkens LH, et al. Lancet Oncol. 2015 Dec;16(16):e582-3. doi: 10.1016/S1470-2045(15)00374-5. Lancet Oncol. 2015. PMID: 26678201 No abstract available.
Maintenance therapy for metastatic colorectal cancer.
Giampieri R, Cascinu S. Giampieri R, et al. Lancet Oncol. 2015 Oct;16(13):1281-2. doi: 10.1016/S1470-2045(15)00125-4. Epub 2015 Sep 8. Lancet Oncol. 2015. PMID: 26361970 No abstract available.
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Al-Batran SE, Lange T, Dietrich G, Stoehlmacher J, Tannapfel A, Reinacher-Schick A, Quidde J, Trarbach T, Hinke A, Schmoll HJ, Arnold D. Hegewisch-Becker S, et al. Lancet Oncol. 2015 Oct;16(13):1355-69. doi: 10.1016/S1470-2045(15)00042-X. Epub 2015 Sep 8. Lancet Oncol. 2015. PMID: 26361971 Clinical Trial.
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB 3rd, Mulkerin DL, Mayer RJ, Blanke C. Venook AP, et al. JAMA. 2017 Jun 20;317(23):2392-2401. doi: 10.1001/jama.2017.7105. JAMA. 2017. PMID: 28632865 Free PMC article. Clinical Trial.
Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
Romera A, Peredpaya S, Shparyk Y, Bondarenko I, Mendonça Bariani G, Abdalla KC, Roca E, Franke F, Melo Cruz F, Ramesh A, Ostwal V, Shah P, Rahuman SA, Paravisini A, Huerga C, Del Campo García A, Millán S. Romera A, et al. Lancet Gastroenterol Hepatol. 2018 Dec;3(12):845-855. doi: 10.1016/S2468-1253(18)30269-3. Epub 2018 Sep 24. Lancet Gastroenterol Hepatol. 2018. PMID: 30262136 Clinical Trial.
91 results